About Us
Submissions
Advertising
SIGN IN
|
SUBSCRIBE
Issue
Recently Published
Current
Archive
Supplements
Events
JADPRO Live
JADPRO Workshop
CE
Patient Ed
Special Content
Resource Centers
Multiple Myeloma
Biomarkers in NSCLC
Bone Protection
CAR-T
Chronic Lymphocytic Leukemia
DLBCL
GVHD
Metastatic HER2+ Breast Cancer
Metastatic Triple-Negative Breast Cancer
MPN
Renal Cell Carcinoma
Roundtable Series
BCL-2 Inhibition in CLL
Follicular Lymphoma
Early-Stage Multiple Myeloma
BTKi in CLL
HR+/HER2- Breast Cancer
HER2-mutant NSCLC
CLL and COVID
Multiple Myeloma
R/R Multiple Myeloma
Bone Health
Myelofibrosis
Updates
Cardio-Oncology
Benign Hematology
Expert Conversations
Clinical Case Series
APSHO Educator Modules
Highlights
Podcast
Society
Learn more on this topic:
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
What data from clinical trials do the FDA consider when approving new drugs for solid tumors?
Edward Li, PharmD, MPH, BCOP
Edward Li, PharmD, MPH, BCOP
, on solid tumors: new drug approvals.
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.
